Novo Nordisk
NVO
660 hedge funds and large institutions have $9.35B invested in Novo Nordisk in 2020 Q2 according to their latest regulatory filings, with 71 funds opening new positions, 194 increasing their positions, 270 reducing their positions, and 49 closing their positions.
145% more call options, than puts
Call options by funds: $79.4M | Put options by funds: $32.5M
45% more first-time investments, than exits
New positions opened: 71 | Existing positions closed: 49
2% more funds holding
Funds holding: 644 → 660 (+16)
2% less capital invested
Capital invested by funds: $9.5B → $9.35B (-$150M)
1.13% less ownership
Funds ownership: 16.96% → 15.83% (-1.1%)
24% less funds holding in top 10
Funds holding in top 10: 21 → 16 (-5)
28% less repeat investments, than reductions
Existing positions increased: 194 | Existing positions reduced: 270
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$166M |
| 2 |
Renaissance Technologies
New York
|
+$54.2M |
| 3 |
Fayez Sarofim & Co
Houston,
Texas
|
+$53.5M |
| 4 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$46.3M |
| 5 |
Two Sigma Investments
New York
|
+$23.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$579M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$165M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
-$80.8M |
| 4 |
Boston Partners
Boston,
Massachusetts
|
-$75.2M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$52.8M |
NVO Hedge Fund Activity: Q2 2020 in Review
660 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q2 2020, worth a combined $9.35B — down 1.6% from $9.5B a quarter earlier.
Buyers outnumbered sellers: 71 funds opened new NVO positions and 49 closed out — a net gain of 22 holders — while 194 added to existing stakes and 270 trimmed.
The largest buyer was Capital International Investors, adding an estimated $166M. The largest seller was Loomis, Sayles & Company, cutting an estimated $579M.
- 660 institutional investors held Novo Nordisk (NVO) as of Q2 2020, up from 644 in Q1 2020.
- Funds reported $9.35B of Novo Nordisk stock for Q2 2020, down 1.6% quarter-over-quarter.
- 71 funds opened new Novo Nordisk positions in Q2 2020 and 49 closed out, a net change of +22 holders.
- The largest Novo Nordisk buyer in Q2 2020 was Capital International Investors, an estimated $166M added.
- The largest Novo Nordisk seller in Q2 2020 was Loomis, Sayles & Company, an estimated $579M sold.
Based on aggregated 13F filings for Q2 2020.